PD-L1 expression and Tumor Mutation Burden (TMB) are associated with immunotherapy benefit in NSCLC and other solid malignancies; however, no predictive value has so far been demonstrated for chemoimmunotherapy in ES-SCLC (11). The gene discussed is CD274; the disease is neoplasm.